Journal of Clinical Oncology · 2010 · 194 citations · 21 references
MedicineOncologyPharmacologyNeuro-oncologyPediatric OncologyPharmacokinetics Of Anticancer AgentsBrain TumorsCentral Nervous System Tumor PharmacotherapyNeuro-oncology ImagingPediatric Brain TumorsPediatric Neuro-oncologyPharmacokinetics In Children With CancerDiffuse Intrinsic Glioma ImagingPediatric Brain Tumor ImagingPediatric Neuro-oncology TrialsPhase Ii InvestigationProgressive Disease AssessmentProgressive Disease QuantificationSurvival RatesTumor Vascular Permeability
A phase II trial administered bevacizumab plus irinotecan to children with recurrent malignant glioma or brainstem glioma, giving two initial bevacizumab doses followed by combined therapy every two weeks and incorporating correlative imaging, pharmacokinetic, and VEGFR‑2 phosphorylation analyses. The combination showed minimal efficacy, with no sustained responses, median progression times of 127 days (malignant glioma) and 71 days (brainstem glioma), 6‑month progression‑free survival rates of 41.8 % and 9.7 %, and manageable but notable toxicities including fatigue, hypertension, CNS hemorrhage, and ischemia.
A phase II study of bevacizumab (BVZ) plus irinotecan (CPT-11) was conducted in children with recurrent malignant glioma (MG) and intrinsic brainstem glioma (BSG).Eligible patients received two doses of BVZ intravenously (10 mg/kg) 2 weeks apart and then BVZ plus CPT-11 every 2 weeks until progressive disease, unacceptable toxicity, or a maximum of 2 years of therapy. Correlative studies included diffusion weighted and T1 dynamic contrast-enhanced permeability imaging, BVZ pharmacokinetics, and estimation of vascular endothelial growth factor receptor 2 (VEGFR-2) phosphorylation in peripheral blood mononuclear cells (PBMC) after single-agent BVZ.Thirty-one evaluable patients received a median of two courses of BVZ plus CPT-11 (range, 1 to 19). No sustained responses were observed in either stratum. Median time to progression for all 34 eligible patients enrolled was 127 days for MG and 71 days for BSG. Progression-free survival rates at 6 months were 41.8% and 9.7% for MG and BSG, respectively. Toxicities related to BVZ included grade 1 to 3 fatigue in seven patients, grade 1 to 2 hypertension in seven patients, grade 1 CNS hemorrhage in four patients, and grade 4 CNS ischemia in two patients. The mean diffusion ratio decreased after two doses of BVZ in patients with MG only. Vascular permeability parameters did not change significantly after therapy in either stratum. Inhibition of VEGFR-2 phosphorylation in PBMC was detected in eight of 11 patients after BVZ exposure.BVZ plus CPT-11 was well-tolerated but had minimal efficacy in children with recurrent malignant glioma and brainstem glioma.
21
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman, Michael D. Prados, Patrick Y. Wen et al. · Journal of Clinical Oncology · 2009 · 2.4K citations
Medicine, Oncology, Pharmacology +17
Response criteria for phase II studies of supratentorial malignant glioma.
David R. Macdonald, T L Cascino, S. Clifford Schold et al. · Journal of Clinical Oncology · 1990 · 2.4K citations
A Perivascular Niche for Brain Tumor Stem Cells
Christopher Calabrese, Helen Poppleton, Mehmet Koçak et al. · Cancer Cell · 2007 · 2.2K citations · Full text